Article Text

PDF

DGI-043 Increased Cost of Erythropoiesis-Stimulating Agents in Some Special Situations
  1. V Escudero-Vilaplana1,
  2. JM López-Gómez2,
  3. A Vega-Martínez2,
  4. A Ais-Larisgoitia1,
  5. B Marzal-Alfaro1,
  6. I Yeste-Gómez1,
  7. A Ribed-Sánchez1,
  8. P Arrabal-Durán1,
  9. A Giménez-Manzorro1,
  10. M Sanjurjo-Sáez1
  1. 1Hospital General Universitario Gregorio Marañón, Pharmacy, Madrid, Spain
  2. 2Hospital General Universitario Gregorio Marañón, Nephrology, Madrid, Spain

Abstract

Background Situations such as a previous kidney transplant or dialysis may increase the dose requirement of erythropoiesis-stimulating agents (ESAs), which is associated with a higher cost.

Purpose To examine the difference in cost between the use of ESAs for pre-dialysis and dialysis (peritoneal dialysis or haemodialysis) patients and for patients with or without a kidney transplant.

Materials and Methods A descriptive, transversal study was carried out in patients treated with ESAs for anaemia secondary to chronic kidney disease in a tertiary hospital over a month in 2011. ESAs used were: epoetin (α or β), darbepoetin α and continuous erythropoietin receptor activator (CERA). The principal variable was patient-month cost, calculated as the cost of the dose unit for each ESA type (IU or mcg) multiplied by the monthly dose per patient.

Results 333 patients were included. 26.2% had previously had a kidney transplant (10.3% epoetin, 33.3% darbepoetin α, 56.3% CERA). Median [p25, p75] patient-month cost for patients with kidney transplant vs. patients who had not had a kidney transplant was: epoetin (191.3 [95.6, 414.5] euros vs. 103.2 [63.8, 191.3] euros, p = 0.060), darbepoetin α (144.0 [72.0, 288.0] euros vs. 144.0 [72.0, 216.0] euros, p = 0.136) and CERA (196.7 [172.1, 295.0] euros vs. 98.3 [59.0, 147.5] euros, p < 0.001).

30.9% patients were on dialysis (35.0% epoetin, 58.3% darbepoetin α, 6.8% CERA). Median [p25, p75] patient-month cost for patients on dialysis vs. not yet on dialysis was: epoetin (151.1 [74.1, 239.1] euros vs. 92.1 [59.5, 165.6] euros, p = 0.006), darbepoetin α (144.0 [72.0, 216.0] euros vs. 144.0 [67.2, 229.2] euros, p = 0.888) and CERA (393.4 [98.3, 491.7] euros vs. 147.5 [98.3, 196.7] euros, p = 0.035).

Conclusions The cost of epoetin and CERA is greater for both patients with a kidney transplant and patients on dialysis. However there was no difference regarding darbepoetin α.

No conflict of interest.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.